Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E-4031是甲磺酰苯胺III 类抗心律失常药,选择性地阻断hERG 钾通道。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 262 | 现货 | ||
2 mg | ¥ 369 | 现货 | ||
5 mg | ¥ 545 | 现货 | ||
10 mg | ¥ 971 | 现货 | ||
25 mg | ¥ 1,920 | 现货 | ||
50 mg | ¥ 2,950 | 现货 | ||
100 mg | ¥ 4,350 | 现货 |
产品描述 | E-4031 is a methanesulfonanilide class III antiarrhythmic agent that prolongs cardiac action potential duration by blocking ERG K+ channels (IC50 = 29 nM) |
靶点活性 | ERG K+ channel (human):29 nM |
体内活性 | At baseline, APD was longer in LQT1 than in LMC rabbits in LV apex and RV mid. Erythromycin and E-4031prolonged APD in LQT1 and LMC rabbits in all positions. However, erythromycin-induced percentaged APD prolongation related to baseline (%APD) was more pronounced in LQT1 at LV base-lateral and RV mid positions (100 μM, LQT1, +40.6 ± 9.7% vs. LMC, +24.1 ± 10.0%, p<0.05) and E-4031-induced %APD prolongation was more pronounced in LQT1 at LV base-lateral (0.01 μM, LQT1, +29.6 ± 10.6% vs. LMC, +19.1 ± 3.8%, p<0.05) and LV base-septal positions. Moreover, erythromycin significantly increased spatial APD dispersion only in LQT1 and increased triangulation only in LQT1 in LV base-septal and RV mid positions. Similarly, E-4031 increased triangulation only in LQT1 in LV apex and base-septal positions[1] |
动物实验 | Hearts of adult female transgenic LQT1 and wild type littermate control (LMC) rabbits were Langendorff-perfused with increasing concentrations of HERG/IKr-blockers E-4031 (0.001-0.1 μM, n=9/7) and APD, APD dispersion, and triangulation were analyzed[1]. |
别名 | (1S)-1,5-脱水-1-C-[4-氯-3-[[4-[2-(环丙氧基)乙氧基]苯基]甲基]苯基]-D-山梨醇 |
分子量 | 474.44 |
分子式 | C21H29Cl2N3O3S |
CAS No. | 113559-13-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 50 mg/mL (105.39 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
H2O | 1 mM | 2.1077 mL | 10.5387 mL | 21.0775 mL | 52.6937 mL |
5 mM | 0.4215 mL | 2.1077 mL | 4.2155 mL | 10.5387 mL | |
10 mM | 0.2108 mL | 1.0539 mL | 2.1077 mL | 5.2694 mL | |
20 mM | 0.1054 mL | 0.5269 mL | 1.0539 mL | 2.6347 mL | |
50 mM | 0.0422 mL | 0.2108 mL | 0.4215 mL | 1.0539 mL | |
100 mM | 0.0211 mL | 0.1054 mL | 0.2108 mL | 0.5269 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
E-4031 113559-13-0 Angiogenesis JAK/STAT signaling Membrane transporter/Ion channel Tyrosine Kinase/Adaptors EGFR Potassium Channel Inhibitor anti-arrhythmic E4031 KcsA inhibit hERG E 4031 (1S)-1,5-脱水-1-C-[4-氯-3-[[4-[2-(环丙氧基)乙氧基]苯基]甲基]苯基]-D-山梨醇 inhibitor